$PVCT,Provectus Biopharmaceuticals Awarded Patent Extending Protection of the PV-10 Manufacturing Process
2 hours 17 minutes ago - DJNF
KNOXVILLE, Tenn.--(BUSINESS WIRE)--March 01, 2016--
Provectus Biopharmaceuticals, Inc. (NYSE MKT: $PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"
, today announced that it has received a patent from the U.S. Patent and Trademark Office, U.S. Patent No. 9,273,022. The patent extends the scope of protection of the manufacturing process conferred initially by U.S. Patent No. 8,530,675, issued in 2013, to include coverage of the use of an alternative raw material in manufacturing the active ingredient (API) in PV-10.
Provectus believes that this patent, wholly owned by Provectus and conferring coverage to at least 2031, will provide further protection around the proposed commercial process for manufacturing PV-10. Investigational drug product generated using this proprietary technology is being used in all ongoing clinical trials of PV-10, including the pivotal phase 3 trial in melanoma (NCT02288897).
Provectus' efforts to bring this process development to fruition were supported by Cambrex Charles City, Inc., a subsidiary of Cambrex Corporation (NYSE:CBM, www.cambrex.com), a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.
Dr. Eric Wachter, CTO of Provectus, noted, "It is a pleasure to have Cambrex team members as co-inventors on this process patent. Although the scientists and engineers working behind the scenes aren't always visible to patients or shareholders, these professionals work tirelessly to enable manufacturing the active ingredient in PV-10 on a commercial scale. Chemistry, Manufacturing and Controls (CMC) is a critical part of any investigational new drug (IND) application and subsequent new drug application (NDA), and this aspect of our PV-10 submission is built on a firm foundation, due in no small part to the efforts of the Cambrex team."
Dr. Kurt Kiewel, Director of R&D at Cambrex Charles City, said, "We feel fortunate to bring the depth of our experience in custom development and API manufacturing to support promising investigational products like PV-10. It has been our pleasure to work with the innovative scientists at Provectus to help advance this potential new cancer treatment toward the market."
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
-- our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of PV-10
to treat locally advanced cutaneous melanoma and the costs associated
with such a trial if it is necessary to complete (versus interim data
alone);
-- our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the liver,
if such licensure is appropriate considering the timing and structure of
such a license, or to commercialize PV-10 on our own to treat melanoma
and other solid tumors such as cancers of the liver;
-- our ability to license PH-10, our investigational drug product for
dermatology, on the basis of our phase 2 atopic dermatitis and psoriasis
results, which are in the process of being further developed in
conjunction with mechanism of action studies; and
-- our ability to raise additional capital if we determine to commercialize
PV-10 and/or PH-10 on our own, although our expectation is to be acquired
by a prospective pharmaceutical or biotech concern prior to
commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005312/en/
CONTACT: Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, Interim CEO, CFO, COO, 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
DM, SVP -- Investor Relations
or
Allison + Partners
Todd Aydelotte, 646-428-0644
Managing Director - Media Relations
SOURCE: Provectus Biopharmaceuticals, Inc.
Copyright Business Wire 2016
(END) Dow Jones Newswires
March 01, 2016 06:00 ET (11:00 GMT
2 hours 17 minutes ago - DJNF
KNOXVILLE, Tenn.--(BUSINESS WIRE)--March 01, 2016--
Provectus Biopharmaceuticals, Inc. (NYSE MKT: $PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"
, today announced that it has received a patent from the U.S. Patent and Trademark Office, U.S. Patent No. 9,273,022. The patent extends the scope of protection of the manufacturing process conferred initially by U.S. Patent No. 8,530,675, issued in 2013, to include coverage of the use of an alternative raw material in manufacturing the active ingredient (API) in PV-10. Provectus believes that this patent, wholly owned by Provectus and conferring coverage to at least 2031, will provide further protection around the proposed commercial process for manufacturing PV-10. Investigational drug product generated using this proprietary technology is being used in all ongoing clinical trials of PV-10, including the pivotal phase 3 trial in melanoma (NCT02288897).
Provectus' efforts to bring this process development to fruition were supported by Cambrex Charles City, Inc., a subsidiary of Cambrex Corporation (NYSE:CBM, www.cambrex.com), a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.
Dr. Eric Wachter, CTO of Provectus, noted, "It is a pleasure to have Cambrex team members as co-inventors on this process patent. Although the scientists and engineers working behind the scenes aren't always visible to patients or shareholders, these professionals work tirelessly to enable manufacturing the active ingredient in PV-10 on a commercial scale. Chemistry, Manufacturing and Controls (CMC) is a critical part of any investigational new drug (IND) application and subsequent new drug application (NDA), and this aspect of our PV-10 submission is built on a firm foundation, due in no small part to the efforts of the Cambrex team."
Dr. Kurt Kiewel, Director of R&D at Cambrex Charles City, said, "We feel fortunate to bring the depth of our experience in custom development and API manufacturing to support promising investigational products like PV-10. It has been our pleasure to work with the innovative scientists at Provectus to help advance this potential new cancer treatment toward the market."
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014) and the following:
-- our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of PV-10
to treat locally advanced cutaneous melanoma and the costs associated
with such a trial if it is necessary to complete (versus interim data
alone);
-- our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the liver,
if such licensure is appropriate considering the timing and structure of
such a license, or to commercialize PV-10 on our own to treat melanoma
and other solid tumors such as cancers of the liver;
-- our ability to license PH-10, our investigational drug product for
dermatology, on the basis of our phase 2 atopic dermatitis and psoriasis
results, which are in the process of being further developed in
conjunction with mechanism of action studies; and
-- our ability to raise additional capital if we determine to commercialize
PV-10 and/or PH-10 on our own, although our expectation is to be acquired
by a prospective pharmaceutical or biotech concern prior to
commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005312/en/
CONTACT: Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, Interim CEO, CFO, COO, 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
DM, SVP -- Investor Relations
or
Allison + Partners
Todd Aydelotte, 646-428-0644
Managing Director - Media Relations
SOURCE: Provectus Biopharmaceuticals, Inc.
Copyright Business Wire 2016
(END) Dow Jones Newswires
March 01, 2016 06:00 ET (11:00 GMT
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
